HO CHI MINH CITY, January 10, 2022, Pfizer (Vietnam) Limited Company and Cho Ray Hospital signed a memorandum of understanding (MoU) to advance antimicrobial awareness and antimicrobial stewardship through a project called “The Partnership with Cho Ray Hospital on Antimicrobial Stewardship (AMS) Program”
The signing ceremony between Pfizer and Cho Ray Hospital is aiming to develop Antimicrobial stewardship partnership program
The problem of antimicrobial resistance (AMR) poses a significant threat to public health, animal health and the environment. Consequently, this reduces the effectiveness of antibiotics, leading to multi- (MDR) and extensively drug-resistant (XDR) pathogens. Furthermore, AMR also has grave economic impacts leading to higher medical costs and prolonged hospital stays.
World Health Organization (WHO) estimates that countries in Southeast Asia are at the highest risk globally of antimicrobial resistance (AMR). Among the countries, Vietnam was one of the first countries in Asia to develop a National Action Plan against it in 2013. However, the increase in antibiotic consumption in hospitals and the community, as well as the overuse of antimicrobial drugs in the animal health sector after the Covid-19 pandemic evolve many challenges to Antimicrobial Stewardship Program.
Aiming to increase awareness about antimicrobial resistance, Pfizer has been working on the antimicrobial stewardship (AMS) program in Vietnam by co-organizing a series of scientific workshops, and campaigns with national hospitals, universities and medical associations. In the upcoming time, Pfizer will focus on strengthening cooperation in executing Antimicrobial Stewardship Partnership program nation-wide.
The program is planned to be implemented with 7 main topics as follows: Scientific conference; AMS training program; Intensivist app for training; Support for early diagnosis; AMS forum; Raising awareness about Antimicrobial Resistance (AMR) awareness for patients; Increasing community knowledge about AMS; AMS surveillance.
Dr Nguyen Tri Thuc, Director of Cho Ray Hospital, gives a speech at the ceremony.
Dr. Nguyen Tri Thuc, Director of Cho Ray Hospital, stated: “We highly appreciate this cooperation program as its contributions include: increasing awareness about antimicrobial resistance among healthcare professionals and public; promoting the development of policies to improve effectiveness of antibiotics; and supporting the implementation and dissemination of the fight against antimicrobial resistance in Vietnam.”
Bác sĩ Nguyễn Tri Thức, Giám đốc Bệnh viện Chợ Rẫy nhận định: “Chúng tôi đánh giá cao chương trình hợp tác này khi góp phần nâng cao nhận thức về kháng kháng sinh cho các cán bộ y tế và cộng đồng, thúc đẩy việc xây dựng chính sách cải thiện hiệu quả của thuốc kháng sinh, góp phần thực hiện và phổ biến công tác chống tình trạng kháng thuốc kháng sinh tại Việt Nam.”
Darrell Oh, General Director at Pfizer Vietnam, gives a speech at the ceremony.
“While Pfizer has sponsored various projects on AMS globally, we recognize that AMR can only be prevented with the combination of good stewardship and innovative antibiotics. That is why we are continuing to focus on our R&D and propose an appropriate usage of antimicrobial agents to preserve their effectiveness. Ultimately, addressing AMR timely can bring long-term benefits to health and development in Vietnam, therefore we need collective efforts and bold innovations to truly win this battle.” said Darrell Oh, General Director at Pfizer Vietnam.
About Cho Ray Hospital:
Cho Ray is a Special-class General Hospital, directly under the Ministry of Health, a hospital with the function of scientific research, educating and training to improve medical knowledge, raise awareness about the responsibility of use of pharma products, combating antibiotic resistance for Vietnamese healthcare professionals of Cho Ray and hospitals at lower level.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
The information contained in this release is as of January 10, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Minh Ha Ho
+84 987 530 219